Advertisement

Dopamine function in obsessive—compulsive disorder: Growth hormone response to apomorphine stimulation

  • Francesca Brambilla
    Correspondence
    Address reprint requests to Prof. Francesca Brambilla. Centro di Psiconeuroendocrinologia, Dipartmento di Scienze Neuropsichiche, Istituto Scientifico Ospedale S. Raffaele, Via Prinetti 27, Milano 20129, Italy.
    Affiliations
    Psychoneuroendocrine Center and Anxiety Disorders Clinical and Research Unit, Department of Neuropsychiatric Sciences, Istituto Scientifico H. San Raffaele, Milan, Italy
    Search for articles by this author
  • Laura Bellodi
    Affiliations
    Psychoneuroendocrine Center and Anxiety Disorders Clinical and Research Unit, Department of Neuropsychiatric Sciences, Istituto Scientifico H. San Raffaele, Milan, Italy
    Search for articles by this author
  • Giampaolo Perna
    Affiliations
    Psychoneuroendocrine Center and Anxiety Disorders Clinical and Research Unit, Department of Neuropsychiatric Sciences, Istituto Scientifico H. San Raffaele, Milan, Italy
    Search for articles by this author
  • Cinzia Arancio
    Affiliations
    Psychoneuroendocrine Center and Anxiety Disorders Clinical and Research Unit, Department of Neuropsychiatric Sciences, Istituto Scientifico H. San Raffaele, Milan, Italy
    Search for articles by this author
  • Angelo Bertani
    Affiliations
    Psychoneuroendocrine Center and Anxiety Disorders Clinical and Research Unit, Department of Neuropsychiatric Sciences, Istituto Scientifico H. San Raffaele, Milan, Italy
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.
      Indirect observations suggest that the dopaminergic system may be involved in the pathophysiology of obsessive—compulsive disorder (OCD). The dopaminergic function of 15 patients with OCD and 15 age/sex-matched controls was evaluated by measuring the growth hormone (GH) responses to stimulation with the dopaminergic agonist apomorphine (APO), which increases growth hormone-releasing hormone (GHRH), GH, and somatomedine C (SMD-C) secretions. Therefore, we measured basal plasma GH and SMD-C concentrations and GH responses to GHRH stimulation to exclude that a downstream pathology of the somatotropic axis could obscure the significance of the results of the APO test. The response of prolactin (PRL) to APO inhibition were also measured. Basal plasma levels of GH, SMD-C, and PRL, GH responses to GHRH stimulation, and PRL responses to APO inhibition did not differ in the two groups of subjects. GH responses to APO stimulation were blunted in obsessive—compulsive (OC) patients. The emetic response to the same stimulation was stronger in patients than in controls. These responses suggest that in our OC patients there is a dysregulation of the dopaminergic system, which is possibly expressed in different ways in the various areas of the central nervous system.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Abruzzese M
        • Bellodi L
        • Ferri S
        • Scarone S
        Frontal lobe dysfunction in schizophenia and obsessive-compulsive disorder: A neuropsychological study.
        Brain Cogn. 1995; 27: 202-212
        • Altemus M
        • Pigott T
        • L'Heureux F
        • et al.
        CSF somatostin in obsessive-compulsive disorder.
        Am J Psychiatry. 1993; 150: 460-464
        • Altemus M
        • Swedo SE
        • Leonard HL
        • et al.
        Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine.
        Arch Gen Psychiatry. 1994; 51: 794-803
        • Altschuler M
        Massive doses of trifluoperazine in the treatment of compulsive rituals.
        Am J Psychiatry. 1962; 19: 376-379
        • American Psychiatry Association
        Diagnostic and Statistical Manual for Mental Disorders.
        3rd ed rev. American Psychiatry Press, Hillsdale, NJ1987
        • Benkelfat C
        • Mefford IN
        • Masters CF
        • et al.
        Plasma catecholamines and their metabolites in obsessive compulsive disorder.
        Psychiatry Res. 1991; 37: 321-332
        • Blanchard M
        • Charrier J
        • Kann G
        • Garandel V
        • Fraysse A
        • Barenton B
        Influence d'un traitement chronique au GRF (1–21) ou au clenbuterol chez la brebis en fin gestation sur la activite' de l'axe somatotrope fetal et maternel.
        Ann Endocrinol (Paris). 1989; 50 ([abstract]): 256
        • Bruto V
        • Beauchamp C
        • Zacharko RM
        • Anisman H
        Amphetamine-induced perseverative behavior in a radial arm maze following DSP4 or 6-OH-DA pretreatment.
        Psychopharmacology (Berl). 1988; 83: 62-69
        • Butler IJ
        • Koslow SH
        • Selfert WE
        • Caprioli RM
        • Singer HS
        Biogenic amine metabolite in Tourette syndrome.
        Ann Neurol. 1979; 6: 37-39
        • Cohen DJ
        • Shaywitz BA
        • Caparulo B
        Chronic, multiple tics of Gilles de la Tourette's disease: CSF acid monoamine metabolites after probenecid administration.
        Arch Gen Psychiatry. 1978; 35: 245-250
        • Comings DE
        • Comings B
        Hereditary agoraphobia and obsessive compulsive behavior in relatives of patients with Gilles de la Tourette's syndrome.
        Br J Psychiatry. 1987; 151: 1229-1241
        • Creese I
        Biochemical properties of CNS dopamine receptors.
        in: Meltzer HY Psychopharmacology: A Third Generation of Progress. Raven Press, Washington, DC1987: 257-264
        • Creese I
        • Iversen SD
        The role of forebrain dopamine systems in amphetamine induced steretyped behavior in the rat.
        Psychopharmacologia. 1974; 39: 345-357
        • De Simoni MG
        • Dal Toso G
        • Fedritto F
        • Sokola A
        • Algeri S
        Modulation of striatal dopamine metabolism by the activity of dorsal raphe serotoninergic afferences.
        Brain Res. 1987; 186: 1-7
        • Devinsky O
        Neuroanatomy of Gilles de la Tourette's syndrome: Possible midbrain involvement.
        Arch Neurol. 1983; 40: 508-514
        • Eilam D
        • Golani I
        • Szechtman H
        D-2 agonist quinpirole induces perseveration of routes and hyperactivity but no perseveration of movements.
        Brain Res. 1989; 490: 225-267
        • Eriksson E
        Experimental Psychoneuroendocrinology.
        Medi Press, New York1985
        • Finenberg NA
        • Cowen PJ
        • Kirk JW
        • Montgomery SA
        Neuroendocrine responses to intravenous L-tryptophan in obsessive compulsive disorder.
        J Affect Disord. 1994; 32: 97-104
        • Frankel M
        • Cummings JL
        • Robertson MM
        • Trimble MR
        • Hill MA
        • Bensons DF
        Obsessions and compulsions in Gilles de la Tourette's syndrome.
        Neurology. 1986; 36: 378-382
        • Frye PE
        • Arnold LE
        Persistent amphetamine-induced compulsive rituals: Response to pyridoxine (B-6).
        Biol Psychiatry. 1981; 16: 583-587
        • Gattaz WF
        • Behrens S
        • De Vry J
        • Hafner H
        Oestradiol hemmt Dopamin-vermittelte Verhaltensweisen bei Rattedn: Ein Tiermodellzur Untersuchung der geschlechtsspezifishen Unterschiede bei der Schizophrenie Fortsch.
        Neurol Psychiat. 1992; 60: 8-16
        • Gattaz WF
        • Vogel P
        • Riecher-Rossler A
        • Soddu G
        Influence of menstrual cycle phase on the therapeutic response in schizophrenia.
        Biol Psychiatry. 1994; 36: 137-139
        • Goodman WK
        • Price LH
        • Rassmussen SA
        • et al.
        The Yale-Brawn obsessive-compulsive scale: I. Development, use, and reliability.
        Arch Gen Psychiatry. 1989; 46: 1006-1011
        • Goodman WK
        • McDougle CJ
        • Price LH
        • Riddle MA
        • Pauls DL
        • Leckman JF
        Beyond the serotonin hypothesis: A role for dopamine in some forms of obsessive compulsive disorder?.
        J Clin Psychiatry. 1990; 51: 36-43
        • Goodman WK
        • McDougle CJ
        • Price LH
        The role of serotonin and dopamine in the pathophysiology of obsessive compulsive disorder.
        Int Clin Psychopharmacol. 1992; 7: 35-38
        • Grad LR
        • Pelcovitz D
        • Olson M
        • Matthews M
        • Grad G
        Obsessive-compulsive symptomatology in children with Tourette's syndrome.
        J Am Acad Child Adolesc Psychiatry. 1987; 1: 69-73
        • Greenberg D
        Compulsive hoarding.
        Am J Psychother. 1987; 41: 409-416
        • Hafner H
        • Berens S
        • De Vry J
        • Gattaz WF
        An animal model for the effects of estradiol on dopamine-mediated behavior: Implications for psychiatry.
        Psychiatry Res. 1991; 38: 125-134
        • Harel Z
        • Shaffer Tannenbaum G
        Dietary protein restriction impairs both spontaneous and growth hormone-releasing factor-stimulated growth hormone release in the rat.
        Endocrinology. 1993; 133: 1035-1043
        • Hollander E
        • Leibowitz MR
        • De Caria CM
        Conceptual and methodological issues in studies of obsessive-compulsive and Tourette's disorders.
        Psychiatr Dev. 1989; 4: 276-296
        • Hollander E
        • Stein DJ
        • Saoud JB
        • et al.
        Effects of fenfluramine on HVA in OCD and controls.
        Biol Psychiatry. 1991; 29: 140A
        • Hollander E
        • Stein DJ
        • Saoud JB
        • et al.
        Effects of fenfluramine on plasma HVA in OCD.
        Psychiatry Res. 1992; 42: 185-188
        • Kelley AE
        • Stinus L
        Disappearance of hoarding behavior after 6-hydroxydopamine lesions of the mesolimbic dopamine neurons and its reinstatement with L-dopa.
        Behav Neurosci. 1985; 99: 531-545
        • Klawans HL
        • Falk DK
        • Nausieda PA
        Gilles de la Tourette syndrome after long-term chlorpromazine therapy.
        Neurology. 1978; 28: 1064-1066
        • Koizumi H
        Obsessive compulsive symptoms following stimulants.
        Biol Psychiatry. 1985; 20: 1332-1337
        • Insel TR
        • Hamilton Guttmacher LB
        • Murphy DL
        Damphetamine in obsessive-compulsive disorder.
        Psychopharmacology (Berl). 1983; 80: 231-235
        • Johnson J
        • Lucey PA
        Encephalitis lethargica, a contemporary causes of catatonic stupor, a report of two cases.
        Br J Psychiatry. 1987; 151: 550-552
        • Lal S
        Apomorphine in the evaluation of dopaminergic function in man.
        Prog Neuropsychopharmacol Biol Psychiatry. 1988; 12: 117-164
        • Leckman JF
        • Goodman WK
        • Anderson GM
        • et al.
        Cerebrospinal fluid biogenic amines in obsessive-compulsive disorder, Tourette's syndrome and healthy controls.
        Neuropsychopharmacology. 1985; 12: 73-86
        • Lowe TL
        • Cohen DJ
        • Detlor J
        • Kremenitzer MW
        • Shaywwitz BA
        Stimulant medications precipitate Tourette's syndrome.
        JAMA. 1982; 247: 1729-1731
        • Marazziti D
        • Hollander E
        • Lensi P
        • Ravagli S
        • Cassano JB
        Peripheral markers of serotonin and dopamine function in obsessive-compulsive disorder.
        Psychiatry Res. 1992; 42: 41-52
        • Masuda A
        • Shibasaki T
        • Nakahara M
        • et al.
        The effect of glucose on growth hormone (GH) releasing hormone-mediated GH secretion in man.
        J Clin Endocrinol Metab. 1985; 60: 523-526
        • McDougle CJ
        • Goodman WK
        • Price LH
        • et al.
        Neuroleptic addition in fluvoxamine-refractory obsessive compulsive disorder.
        Am J Psychiatry. 1990; 147: 652-654
        • McDougle CJ
        • Goodman WK
        • Leckeman JF
        • Lee NC
        • Heninger GR
        • Price LH
        Haloperidol addition in fluvoxaminerefractory obsessive-compulsive disorder.
        Arch Gen Psychiatry. 1994; 51: 302-308
        • Mesulam MM
        Cocaine and Tourette' syndrome.
        N Engl J Med. 1978; 315: 398
        • Model JG
        • Mountz JM
        • Curtis JC
        • Greden JF
        Neurophysiologic dysfunction in basal ganglia/limbic striatal and talamocortical circuits as a pathogenetic mechanism of obsessive compulsive disorder.
        J Neuropsychiatry. 1989; 1: 27-36
        • Muller EE
        Neural control of somatotropic function.
        Physiol Rev. 1987; 3: 962-1053
        • Muller E
        • Nistico' G
        Brain Messengers and the Pituitary.
        Academic Press, Goteborg, Sweden1989
        • Neale JM
        • Oltmanns TF
        Schizophrenia.
        Wiley, New York1988
        • Pauls DL
        • Towbin KE
        • Leckam JF
        • Zahner GEP
        • Cohen DJ
        Gilles de la Tourette's syndrome and obsessive compulsive disorder: Evidence supporting a genetic relationship.
        Arch Gen Psychiatry. 1986; 43: 1180-1182
        • Pauls DL
        • Raymond CL
        • Stevenson JM
        • Leckeman JF
        A family study of Gilles de la Tourette syndrome.
        Am J Hum Genet. 1991; 48: 154-163
        • Pavia C
        • Valls C
        • Gallart M
        Priming with GHRH (1–29)-NH-2 as a useful tool in the origin diagnosis of growth hormone (GH) deficiency.
        Acta Med Auxol. 1993; 25: 133-138
        • Pitman RK
        • Green RC
        • Jenike MA
        • Mesulman MM
        Clinical comparison of Tourette's disorder and obsessivecompulsive disorder.
        Am J Psychiatry. 1987; 4: 267-296
        • Rapaport JL
        • Wise SP
        Obsessive-compulsive disorder: Evidence for basal ganglia dysfunction.
        Psychopharmacol Bull. 1988; 24: 380-384
        • Riecher-Rossler A
        • Hafner H
        • Dutsch-Strobel A
        • et al.
        Further evidence for a specific role of estradiol in schizophrenia?.
        Biol Psychiatry. 1994; 36: 492-497
        • Rivers-Buckeley N
        • Hollender MH
        Succesful treatment of obsessive compulsive disorder with cloxapine.
        Am J Psychiatry. 1982; 139: 1345-1346
        • Robins L
        • Helzer JE
        • Cottler L
        • Goldring E
        NIMH Diagnosis Interview Schedule: Version III-R.
        Washington University Medical School, New York1989
        • Roy BF
        • Benkelfat C
        • Hill JL
        • et al.
        Serum antibody for somatostin-14 and prodynorphin 209–240 in patients with obsessive-compulsive disorder, schizophrenia, Alzheimer's disease, multiple sclerosis and advanced HIV infection.
        Biol Psychiatry. 1994; 35: 335-344
        • Scarone S
        • Colombo C
        • Livian S
        • et al.
        Increased right caudate nucleus size in obsessive-compulsive disorder (OCD), detection with magnetic resonance imaging.
        Psychiatry Res Neuroimaging. 1992; 45: 115-121
        • Schimchowitsch S
        • Palacios JM
        • Stoeckel ME
        • Porte A
        Dopamine D-2 receptors are restricted to the prolactin cells in rabbit pituitary gland: A combined autoradiographic and immunocytochemical study.
        Neurosci Lett. 1986; 70: 314-319
        • Seaman P
        • Van Tol HHM
        Dopamine receptors pharmacology.
        Curr Opin Neurol Neurosurg. 1993; 6: 602-608
        • Shapiro AK
        • Shapiro E
        Evaluation of the reported association of obsessive-compulsive symptoms or disorder with Tourette's disorder.
        Compr Psychiatry. 1992; 33: 156-165
        • Shapiro E
        • Shapiro AK
        • Fulop G
        • et al.
        Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette's syndrome.
        Arch Gen Psychiatry. 1989; 46: 722-730
        • Sibley DR
        • Monsma Jr, FJ
        Molecular biology of dopamine receptors.
        Trends in Pharmacological Sciences. 1992; 13: 61-69
        • Singer HS
        • Butler IJ
        • Seifert WE
        • Coyle JT
        Dopaminergic disfunction in Tourette syndrome.
        Ann Neurol. 1982; 12: 361-366
        • Singer HS
        • Hahn IK
        • Moran TH
        Abnormal dopamine uptake sites in post-mortem striatum from patients with Tourette's syndrome.
        Ann Neurol. 1991; 30: 558-562
        • Skare SS
        • Dysken MW
        • Billington CJ
        A review of the GHRH stimulation test in psychiatry.
        Biol Psychiatry. 1994; 36: 249-265
        • Swedo SE
        • Leonard HL
        • Kruesi MJP
        • et al.
        Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder.
        Arch Gen Psychiatry. 1992; 49: 29-36
        • Takano K
        • Ishiguro T
        A study of clinical pictures and monoamino metabolism of Gilles de la Tourette syndrome.
        Psychiatr Neurol Japanica. 1993; 95: 1-29
        • Thoren P
        • Asberg M
        • Bertilsson L
        • Mellstrom B
        • Sjoqvrist F
        • Trakman L
        Clomipramine treatment of obsessive compulsive disorders: II. Biochemical aspects.
        Arch Gen Psychiatry. 1980; 37: 1289-1294
        • Wallach MB
        Drug-induced stereotyped behavior: Similarities and differences.
        in: Usdin E Neuropsychopharmacology of Monoamines and Their Regulatory Enzymes. Raven Press, St. Louis1974: 241-260
        • Weissberger AJ
        • Ho KY
        • Lazarus L
        Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women.
        J Clin Endocrinol Metab. 1991; 72: 374-381
        • Williams T
        • Berelowitz M
        • Joffe SN
        • et al.
        Impaired growth hormone responses to growth hormone-releasing factor in obesity.
        N Engl J Med. 1984; 211: 1403-1407
        • Wise SP
        • Rapoport JL
        Obsessive compulsive disorder: Is it basal ganglia dysfunction?.
        in: Rapoport JL Obsessive Compulsive Disorder in Children and Adolescents. America Psychiatric Press, New York1989: 327-344